Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP277571.RAwencgC8Z5vzfd-CBPQqY-RKUBZk-66bDTVCKSyiO3dM130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP277571.RAwencgC8Z5vzfd-CBPQqY-RKUBZk-66bDTVCKSyiO3dM130_provenance.
• NP340711.RAiZZIF6agIGVmh-XJG8RDLHxrihPByjrkiYRpCAUFOiw130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP340711.RAiZZIF6agIGVmh-XJG8RDLHxrihPByjrkiYRpCAUFOiw130_provenance.
• NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_provenance.
• NP924199.RAaLjCstQdE39t_6LH7bap7gyLJXYvOMJQflu_D5m6jc8130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP924199.RAaLjCstQdE39t_6LH7bap7gyLJXYvOMJQflu_D5m6jc8130_provenance.
• NP449051.RAkDAIfl_dvroywY3SX5WWF0Dmig7uyO--5VLU3kYjuas130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP449051.RAkDAIfl_dvroywY3SX5WWF0Dmig7uyO--5VLU3kYjuas130_provenance.
• NP781520.RAacTgE_JUhNMvO-JPg0yQkP0Vtq3nkm1GDeiUZOaOSGg130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781520.RAacTgE_JUhNMvO-JPg0yQkP0Vtq3nkm1GDeiUZOaOSGg130_provenance.
• NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_provenance.
• NP526338.RASF-Ty1sStAV6I4klnHdcupFWrJxBlLSeZa3ahaVhpzE130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526338.RASF-Ty1sStAV6I4klnHdcupFWrJxBlLSeZa3ahaVhpzE130_provenance.
• NP978610.RABeu7RpPLcWf6yuSnbxJvL2Cb1aATUDq3PVL13n-oAK0130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978610.RABeu7RpPLcWf6yuSnbxJvL2Cb1aATUDq3PVL13n-oAK0130_provenance.
• NP873264.RAAtLFjOEF8rBre_7P4m20KQ91-nTEAObATnOyx7--uyg130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873264.RAAtLFjOEF8rBre_7P4m20KQ91-nTEAObATnOyx7--uyg130_provenance.
• NP914129.RAucpSz1DcAtvTjbk05XFUQKa9-BOeNTzE3dOOEhusjuk130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914129.RAucpSz1DcAtvTjbk05XFUQKa9-BOeNTzE3dOOEhusjuk130_provenance.
• NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526337.RAgXr0GtUOi-veeqwu3L-UZ0Lbp8nB0I2jeXpzjFsliMs130_provenance.
• NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_provenance.
• NP606091.RAPItWT4QXZQLHQAV_a2mestbb4Zeh1JVBECFFbjV6gTs130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP606091.RAPItWT4QXZQLHQAV_a2mestbb4Zeh1JVBECFFbjV6gTs130_provenance.
• NP526333.RAMqgnqluMOyc9lFYa_wnLuYY11nx6eFtV17CRilm0iw0130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526333.RAMqgnqluMOyc9lFYa_wnLuYY11nx6eFtV17CRilm0iw0130_provenance.
• NP526345.RALi-ExQUIH_SY_vMd6LG8vyNrtl2Tw-kx2-Yx1K9gXmU130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526345.RALi-ExQUIH_SY_vMd6LG8vyNrtl2Tw-kx2-Yx1K9gXmU130_provenance.
• NP526334.RAwrITOjueal9-ZlfF-1PNgPMMsM6nY6yA3O424k0hHVM130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526334.RAwrITOjueal9-ZlfF-1PNgPMMsM6nY6yA3O424k0hHVM130_provenance.
• NP526335.RAyhtPi8XBy2rjGxdFy6Bt5QKCBqHJkFmYgKNd_YLU4_Y130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526335.RAyhtPi8XBy2rjGxdFy6Bt5QKCBqHJkFmYgKNd_YLU4_Y130_provenance.
• NP526343.RA1RiSTuvc7bZcbXQx8uRfu67h0H6IWRF-PG_IfFbPA2o130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526343.RA1RiSTuvc7bZcbXQx8uRfu67h0H6IWRF-PG_IfFbPA2o130_provenance.
• NP526344.RAxssy3cjpaJd2d9OgRgmplQz1Qx0l2rP_WShn5kiLtYI130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526344.RAxssy3cjpaJd2d9OgRgmplQz1Qx0l2rP_WShn5kiLtYI130_provenance.
• NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_provenance.